HDAC9 and cystic fibrosis: Thus, further clinical evaluation of this potent pharmaceutical strategy is warranted, and we anticipate that using the specific HDAC-inhibitors [3, 17] and novel nano-based drug delivery system [49], that we recently described, can further enhance its therapeutic potency in reverting the CF-lung disease.